Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis-Reference-Cited by-同舟云学术

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Published:2013-01-07 Issue:2 Volume:28 Page:192-203
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Mamolo C.¹,Harness J.¹²,Tan H.¹,Menter A.³

Affiliation:

1. Pfizer Inc; Groton CT USA

2. Novartis Pharma AG; Basel Switzerland

3. Baylor Research Institute; Dallas TX USA

Funder

Pfizer Inc

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.12081/fullpdf

Reference30 articles.

1. Biological agents in the treatment of psoriasis;Tzu;G Ital Dermatol Venereol,2008

2. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents;Menter;J Am Acad Dermatol,2009

3. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey;Dubertret;Br J Dermatol,2006

4. Psoriasis and the metabolic syndrome;Gottlieb;J Drugs Dermatol,2008

5. Psoriasis and diabetes: a population-based cross-sectional study;Cohen;J Eur Acad Dermatol Venereol,2008

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of JAK-STAT Inhibitors in the Treatment of Moderate to Severe Plaque Psoriasis: a Meta Analysis;Journal of Contemporary Medical Practice;2024-07-28

2. Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature;International Journal of Molecular Sciences;2024-04-25

3. Janus kinase inhibitors: A new therapeutic option for autoimmune diseases;Studies in Medical Sciences;2024-02-01

4. SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis;Frontiers in Immunology;2023-10-26

5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12